| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
At BioPharma Diagnostics, we are inspired by Mayo Clinic’s history of collaboration and breaking down barriers to change medicine. That’s why we bring Mayo Clinic expertise and quality to each project — from consulting through discovery to post-regulatory lab needs. Together we have the power to improve global health.
24/7/365
24/7/365 accessibility: Our call center is staffed all day, every day, enabling connections with laboratory experts
99.99%
99.99% successful specimen delivery rate
200+
200+ couriers and carriers in logistics network
BioPharma Diagnostics provides a wide range of testing solutions to support research and development teams within the pharmaceutical, biotech, and in vitro diagnostics industries and their collaborators, such as CROs. This includes laboratory testing solutions, diagnostic development, and validation and biomarker services.
Each solution aligns the expertise and resources of Mayo Clinic with our partners’ needs and research programs of all sizes. Our teams and our proven approach eliminate barriers and simplify complexity. We offer direct access to:
Highlights
Mayo Clinic Laboratories is excited to participate in the 65th ASH Annual Meeting & Exposition, which will take place in San Diego on Dec. 9–12, 2023.
The nonprofit patient advocacy group called The MOG Project supports patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which is a rare and debilitating central nervous system demyelinating disorder. A team of Mayo Clinic neurologists, neuro-ophthalmologists, and the Autoimmune Neurology Laboratory at Mayo Clinic share a unique relationship with The MOG Project as they harness the power of patients’ experiences with MOGAD and their biospecimen data to advance the science behind this disease.
Mayo Clinic launched an automated system called RENEW — reanalysis of negative whole-exome/genome data — in 2022 that tracks newly published discoveries of disease-causing genetic variants. Every three months, the system automatically uploads these new scientific findings from around the world, which are then compared to the Mayo Clinic Center for Individualized Medicine’s database of unsolved patient sequencing results. This comparison helps to identify potentially significant developments that could lead to a new diagnosis for a patient with a rare genetic disorder.
Mayo Clinic Laboratories offers a ceremide test to advise patients and their clinicians of the potential risk of heart attack. Using liquid chromatography-mass spectrometry technology, the test renders an algorithmic score after sorting through molecular compounds of ceramides of cardiovascular interest. Ceramide testing can be used alongside traditional blood tests to investigate risk factors of coronary artery disease.
Mayo Clinic Laboratories’ MayoComplete Melanoma Panel is a comprehensive test that better informs the prognosis and treatment of melanoma. It can be applied to unusual tumors that haven’t yet been identified as melanoma as well as melanomas with complex molecular structures.
At Mayo Clinic, quality is not an act, it’s a habit. This commitment extends into BioPharma Diagnostics, where a team of four quality assurance assistants and three lab processing assistants has recently come together as the BioPharma Accessioning Pod. Their focus includes accommodating the unique requirements of BioPharma clinical trials and research samples during accessioning and sharing data and findings with the BioPharma Diagnostics team.
Mayo Clinic Laboratories has developed a new colorectal cancer test, the MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC), in response to the latest recommendations for testing and treatment from the American Society of Clinical Oncology.
The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST.
Mayo Clinic Laboratories’ new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG) provides more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.
Mayo Clinic researchers and collaborators have discovered a critical role that inflammation plays in liver regeneration after liver resection. While effective regeneration requires some inflammation, too much of it causes regeneration failure. They also discovered that patients experiencing dysfunctional liver regeneration had a significantly dysregulated gene known as DUSP4 – a finding that could help support targeted therapeutic strategies administered before or after surgical resection to prevent liver failure.
Mayo Clinic Laboratories has developed a new direct ethanol biomarker test for alcohol consumption that has a much longer detection window than existing urine tests for alcohol use.
Mayo Clinic researchers are now using artificial intelligence (AI) systems to help increase polyp detection during colonoscopies and identify colorectal cancer at an early stage. Like facial recognition software that recognizes faces, this AI tool is being trained to recognize polyps. It works alongside the physician during a colonoscopy, scanning the video feed and drawing boxes around polyps that may otherwise have been overlooked due to their subtleness.